Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Factors associated with psychosis in patients with Parkinson's disease
Movement Disorders
P12 - Poster Session 12 (12:00 PM-1:00 PM)
3-010

Identify demographic and clinical factors associated with psychosis in patients with Parkinson's disease (PD).

PD is a neurodegenerative disorder with motor and non-motor characteristics, which include psychiatric symptoms1, including psychosis that contributes significantly to morbidity and mortality2.
Comparative, descriptive and analytical cross-sectional observational study. A cohort of the Mexican Study Group in Parkinson was used, 306 subjects evaluated in the last year were included. A univariate analysis was made between demographic and clinical variables and the outcome of the presence of psychosis and a multiple logistic regression model to identify predictive factors

Of the 306, 55 (18%), presented psychosis. In the univariate analysis, the variables that were associated with psychosis were: the duration of the disease in years (p = <0.001, RM 2.83), years since diagnosis (p = <0.001, RM 3.90), non-motor symptoms (part I MDS-UPDRS) (p = <0.001, RM 29.62), and severity in motor symptoms (part III MDS-UPDRS) (p = 0.016, RM 10.43). In the linear regression model, the duration of the disease in years (p = 0.007, RM 1.094), sleep disorders (p = 0.19, RM 2.57) and non-motor symptoms (part I MDS-UPDRS) ((p = <0.001 , RM 0.24) proved to be significant predictors for psychosis, while the use of COMT inhibitors (p = 0.001, RM 0.094) and apathy (p = <0.001, RM 0.462) were shown to be protective factors.

Similar to previous studies, we found that the duration of the disease in years, years since diagnosis, sleep disorders, presence of non-motor symptoms and severity in motor symptoms can help identify patients with psychosis.

Apathy and, not previously reported, the use of COMT inhibitors could be protective factors.
Authors/Disclosures

PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Antonio Anaya-Escamilla, MD (CHRISTUS MUGUERZA Hospital Sur) No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Mayela D. Rodriguez Violante, MD (Instituto Nacional de Neurología y Neurocirugía) Dr. Rodriguez Violante has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boston Scientific. Dr. Rodriguez Violante has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sandoz Novartis. Dr. Rodriguez Violante has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zydus. The institution of Dr. Rodriguez Violante has received research support from LARGE-PD.
Daniel Martinez-Ramirez, MD (Oncare) Dr. Martinez-Ramirez has nothing to disclose.